Sugi Predict

Sugi Predict / Compounds / SCHEMBL699665

SCHEMBL699665

SCHEMBL699665

CCOC(=O)c1cc2c(Cl)c(Cl)ccc2[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 1/20 0.57
▸ ALDH1A1 P00352 8/20 0.56
▸ KDM4E B2RXH2 7/20 0.56
▸ RAB9A P51151 6/20 0.56
▸ HPGD P15428 6/20 0.56
▸ SMN1; SMN2 Q16637 4/20 0.56
▸ HSD17B10 Q99714 2/20 0.56
▸ NPC1 O15118 4/20 0.52
▸ LMNA P02545 2/20 0.52
▸ HTT P42858 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ HRH3 Q9Y5N1 1/20 0.52
▸ HRH4 Q9H3N8 1/20 0.52
▸ MMP13 P45452 4/20 0.51
▸ MAPT P10636 4/20 0.51
▸ MMP2 P08253 3/20 0.51
▸ GAA P10253 3/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ GLA P06280 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30525427 1.00 ALOX15 (0.57) ALOX15ALDH1A1KDM4ERAB9AHPGD
SCHEMBL7954222 0.89 ALOX15 (0.57) ALOX15ALDH1A1KDM4ERAB9AHPGD
SCHEMBL19332451 0.89 ALOX15 (0.57) ALOX15ALDH1A1KDM4ERAB9AHPGD
SCHEMBL30193757 0.86 ALOX15 (0.58) ALOX15ALDH1A1KDM4ERAB9AHPGD
SCHEMBL1883225 0.86 ALOX15 (0.58) ALOX15ALDH1A1KDM4ERAB9AHPGD
SCHEMBL4403101 0.86 ALOX15 (0.54) ALOX15ALDH1A1KDM4ERAB9AHPGD
SCHEMBL6594500 0.85 ALDH1A1 (0.55) ALOX15ALDH1A1KDM4ERAB9AHPGD
SCHEMBL30039640 0.84 HRH4 (0.56) ALDH1A1KDM4ERAB9AHPGDHSD17B10
SCHEMBL19331400 0.84 HRH4 (0.56) ALDH1A1KDM4ERAB9AHPGDHSD17B10
SCHEMBL4044123 0.83 CDK1 (0.57) ALOX15ALDH1A1KDM4ERAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747234-A1 KV1.3 POTASSIUM CHANNEL ANTAGONISTS Muna Therapeutics ApS (DK) 2026-05-27 — — EP disclosed
US-12404261-B2 Compounds and compositions for treating conditions associated with cGAS NOVARTIS AG (CH) 2025-09-02 — — US disclosed
WO-2025017103-A1 KV1.3 POTASSIUM CHANNEL ANTAGONISTS MUNA THERAPEUTICS APS (DK) 2025-01-23 — — WO disclosed
CN-116635382-A Indole derivatives useful for treating cGAS-related disorders 诺华股份有限公司 2023-08-22 — — CN disclosed
US-20230085472-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH cGAS NOVARTIS PHARMA AG (CH) 2023-03-16 — — US disclosed
WO-2020244462-A1 INDOLE DERIVATIVES AND PHARMACEUTICAL USE THEREOF 中国药科大学 2020-12-10 — — WO disclosed
WO-2017156181-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-09-14 — — WO disclosed
EP-1373204-B1 HETEROCYCLIC COMPOUNDS JANSSEN PHARMACEUTICALS INC (US) 2016-10-26 — — EP disclosed
US-8124766-B2 Inhibitors of diacylglycerol acyltransferase MADRIGAL PHARMACEUTICALS, INC. (US) 2012-02-28 — — US disclosed
US-8124766-B2 Inhibitors of diacylglycerol acyltransferase MADRIGAL PHARMACEUTICALS, INC. (US) 2012-02-28 — — US disclosed
EP-1003504-A2 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS AstraZeneca UK Limited (GB) 2000-05-31 — — EP disclosed
US-5981525-A FOR THERAPY OR PROPHYLAXIS OF OSTEOPOROSIS,TUMOURS, ULCERS, AUTOIMMUNE DISEASES, LIPIDEMIC DISORDERS, HYPERCHOLESTEROLEMIC AND ATHEROSCLEROTIC DISEASES, AIDS ALZHEIMER'S DISEASE SMITHKLINE BEECHAM CORPORATION (US) 1999-11-09 — — US disclosed
US-5977100-A Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1999-11-02 — — US disclosed
WO-1999035130-A1 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS PFIZER PHARMACEUTICALS INC. (JP) 1999-07-15 — — WO disclosed
WO-1999033801-A1 TRIPEPTIDYL PEPTIDASE INHIBITORS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1999-07-08 — — WO disclosed
WO-1999007351-A2 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS ZENECA LIMITED (GB) 1999-02-18 — — WO disclosed
US-5834454-A TREATMENT OF ANGINA, ISCHEMIA, ARRHYTHMIA SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1998-11-10 — — US disclosed
EP-0802902-A1 INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF OSTEOPOROSIS Smithkline Beecham S.p.A. (IT) 1997-10-29 — — EP disclosed
EP-0787728-A1 Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1997-08-06 — — EP disclosed
WO-1996021644-A1 INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF OSTEOPOROSIS SMITHKLINE BEECHAM S.P.A. (IT) 1996-07-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12404261-B2 Compounds and compositions for treating conditions associated with cGAS CGAS, TDP1, IAPP ALOX15 2268/4885ALDH1A1 2159/4885KDM4E 4717/4885
US-20230085472-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH cGAS CGAS, TDP1, IAPP ALOX15 2268/4885ALDH1A1 2159/4885KDM4E 4717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.